Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- ENvue Medical, Inc.ENvue Medical Provides Nasdaq Listing UpdateENvue Medical, Inc. (Nasdaq: FEED) (“ENvue” or the “Company”), a medical technology company focused on innovative solutions for enteral feeding and therapeutic ultrasound, today announced that it has received a decision from the Nasdaq Hearings Panel (the “Panel”) denying the Company’s request for continued listing on The Nasdaq Capital Market. As a result, trading of the Company’s common stock will be suspended and will begin trading on the OTC Markets under the same stock symbol, ‘FEED’, on September 16, 2026.
- AARD Shareholder Alert: Aardvark Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallStA securities class action alleges Aardvark Therapeutics' Chief Executive Officer, Chief Financial Officer, and former Chief Operating Officer controlled the safety representations about ARD-101 that preceded a Phase 3 pause and a full FDA clinical hold
- Mordor Intelligence Private LimitedPediatric Vaccines Market: USD 56.06 Billion by 2031, Growth Fueled by Multivalent Formulations and Next-Generation Vaccine Platforms, Says Mordor IntelligenceAccording to the latest report by Mordor Intelligence, the pediatric vaccines market is estimated at USD 42.53 billion in 2026 and is projected to reach USD 56.06 billion by 2031, registering a CAGR of 5.68% during the forecast period....
- CordenPharma Appoints Dr. Jean-Luc Herbeaux as Chief Executive Officer to Lead Next Phase of GrowthCordenPharma, a leading global pharmaceutical CDMO, announced today the appointment of Dr. Jean-Luc Herbeaux as Chief Executive Officer, effective 1...
- Fort Wayne Medical Oncology and Hematology and Fort Wayne Gynecologic Oncology Consolidate Bluffton and Decatur Clinics at New Decatur LocationFort Wayne Medical Oncology and Hematology and Fort Wayne Gynecologic Oncology Consolidate Bluffton and Decatur Clinics at New Decatur Location
- MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEOMAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 185,078 shares of MAIA common stock were acquired by Mr. Guerrero between August 20, 2026, and September 10, 2026, at an average common stock price of $1.36. MAIA also announced that 73,000 shares of MAIA common stock were acquired by Founder and CEO Vlad Vitoc, M.D. on September 14, 2026, at an average common stock price of $1.37.
- Hagens Berman Sobol Shapiro LLPAardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff DeadlineHagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock...
- NKGen Biotech, Inc.NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy ForumNKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company’s lead investigational program, troculeucel, at the 4th Great Bay Cell and Gene Therapy Forum, taking place September 22-23, 2026, in Guangzhou, China.
- Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM
- 美股异动丨Moleculin Biotech盘前续涨约6%，临床数据预期与学术会议催化格隆汇9月15日｜美股生物医药股MoleculinBiotech(MBRX.US盘前继续上涨约6%，延续了前一交易日的反弹势头。消息面上，公司于9月14日宣布，Annamycin的新数据将在三场科学会议上展示，包括9月25-28日在圣地亚哥举行的AACR会议，以及波兰的两场欧洲学术活动。这些展示将覆盖药物组织分布、作用机制及抗肿瘤活性等方向，市场预期学术曝光可能带来新的数据解读或合作机...
- HmediumFrost & Sullivan Published the White Book on the Current Landscape and Future Trends of the Gut Microbiota IndustryFrost & Sullivan has conducted comprehensive research on the global gut microbiota industry and published the "White Book on the Current Landscape and Future Trends of the Gut Microbiota Industry". The white paper provides a comprehensive overview of gut microbiota, exploring its relationship with health and disease, the current landscape of gut microbiota drug development, market insights, and future trends. The White Book begins by...
- Ascendis PharmaAscendis Announces Planned $400 Million Share Repurchase ProgramAscendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s ordinary shares (the Share Repurchase Program).